Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06462469 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06462469 · ClinicalTrials.gov record · last posted 2026-08-27

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Name: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease — clinical trial record (NCT06462469)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2024-07-04

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Protocol amendment history 3 changes detected by DataLookout

2026-08-28

Enrollment closed, study ongoing

2026-08-22

Primary completion moved earlier: 2027-01-04 → 2026-09-24

2026-08-22

Completion moved earlier: 2028-02-17 → 2027-06-21

Trial Details

NCT Number	NCT06462469
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Steroid-refractory Acute Graft Versus Host Disease
Enrollment	36 participants
Start Date	2024-07-04
Primary Completion	2026-09-02 (estimated)
Study Completion	2027-07-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-27